早期尿激酶静脉溶栓治疗急性心肌梗死24例临床分析

目的 观察早期尿激酶静脉溶栓治疗急性心肌梗死（AMI）的疗效。方法回顾分析24例采用早期尿激酶溶栓治疗与18例采用常规治疗的AMI患者的临床资料，观察溶栓治疗患者的再通情况及溶栓后24h内T波倒置对判断冠脉再通的影响。结果尿激酶治疗组和常规治疗组的冠脉再通率分别为62．5％和15．0％（P〈0．05），发病至开始溶栓的时间越短，再通率越高。结论早期尿激酶静脉溶栓治疗可提高AMI疗效，降低病死率，宜早期应用。

Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases

OBJECTIVE: To observe the therapeutic effect of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction (AMI). METHOD: The clinic data of 24 patients treated with early stage thrombolytic therapy with venous urokinase and 18 conventional therapy were reviewed, and the repatency of the coronary artery and T-wave inversion within 24 h after the treatment were evaluated. RESULT: The repatency rate of urokinase group and conventional therapy group was 62.5% and 15.0%, respectively, showing significant difference (P<0.05). Shorter delay of administration of thrombolytic therapy after infarction onset resulted in higher rate of repatency. CONCLUSION: Early stage thrombolytic therapy with venous urokinase can improve the therapeutic effect and reduce the mortality rate of AMI, and is therefore recommended for clinical application.